A Phase I, Dose-Escalation Study to Assess the Safety and drug levels in blood of AZD4877 in Japanese Adult Patients

Exclusion Criteria

• -Patients who have received treatment with anti-cancer agent within 4 weeks prior to first dose of study treatment; 6 weeks if the anti-cancer agent is mitomycin.
• - Patients with abnormally low levels of neutrophil count, platelet count, or haemoglobin, indicators of bone marrow function.
• - Patients who received therapeutic radiotherapy at central nervous system within 3 months prior to first dose of study treatment; the other sites within 4 weeks; or local site within 2 weeks.